Friday 16 October 2026
Export EVMN’s income statement to Excel — free account
Evommune Inc.
EVMN Healthcare Biotechnology
Evommune Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.0 million, up 85.7% from fiscal 2024. In the quarter to June 2026, EPS grew 89.9% and free cash flow grew 21.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
5.17
0.76
−12.82%
Follow EVMN
Evommune Inc. (EVMN) P/E ratio
Evommune Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2025 | 0.0× | — |
| Mar 2025 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ALEC Alector, Inc. compare | n/m |
| PYXS Pyxis Oncology, Inc. compare | n/m |
| EVMN Evommune Inc. | n/m |
| ZNTL Zentalis Pharmaceuticals, Inc. compare | n/m |
| CAMP CAMP4 Therapeutics Corporation compare | n/m |
| IFRX InflaRx N.V. compare | n/m |
| MGNX MacroGenics, Inc. compare | n/m |
| KROS Keros Therapeutics, Inc. compare | n/m |
| PLX Protalix BioTherapeutics, Inc. compare | 10.9× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)